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We sought to determine the optimal time for measuring peak expiratory flow rate (PEF) in patients with mild to
moderate asthma, before and after treatment with inhaled beclomethasone dipropionate (BDP). After 2 weeks of
observation, BDP (400 mg/d) was given to 22 patients with mild to moderate asthma. The dose of BDP (800–1200
mg/d) was increased every 2 weeks until PEF varied by no more than 20% each day. PEF was measured four times
daily: on awakening, around noon, in the evening and at bedtime. Significant (P5005) rhythms were detected by
single cosinor analysis in all patients, both during observation and during treatment. Analysis by the population
mean–cosinor method showed that the mean mesor was 3788+591 lmin71, the mean amplitude was 539+
134 lmin71, and the mean acrophase was at 16:26+0:32 before treatment. After treatment, the mean mesor was
5280+619 lmin71, the mean amplitude was 376+122 lmin71, and the mean acrophase was at 16:35+0:32. The
mesor increased significantly (P5005), and the amplitude decreased significantly (P5005) after treatment.
The acrophase did not change. These data indicate that PEF is lowest at 04:30 and highest at 16:30 in
patients with mild to moderate asthma, both during observation and during treatment. We conclude that if one
needs to assess PEF twice a day, this should ideally be done at 04:30 and 16:30, not only before but also after
treatment with BDP.
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Increasing morbidity and mortality from asthma (1) have
prompted the development of various means for monitor-
ing the severity of this disease. Home peak expiratory flow
(PEF) monitoring is a widely recommended technique
helpful in the diagnosis and management of asthma that
can provide information about day-to-day airway lability.
PEF measurements are simple, quantitative and reprodu-
cible, and correlate well with FEV1 as measured by
spirometry (2,3). In the individual asthmatic patient, home
PEF monitoring helps to assess the degree of airflow
obstruction and overall severity of disease. Many PEF
indices have been proposed and tested, and daily PEF
variability is most commonly used for the management ofReceived 8 April 1999 and accepted in revised form 10 November
1999.
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0954-6111/00/040385+06 $35?00/0asthma. PEF is as satisfactory as FEV1 for describing
circadian variation among normal subjects and stable
patients with asthma (4). In most studies, patients inhaled
b-agonists two to four times daily (5), but regular use of
inhaled b-agonists does not comply with current therapeu-
tic guidelines, which recommend that b-agonists should be
inhaled as needed to relieve asthma symptoms. Accurate
evaluation of daily PEF variability requires that PEF is
measured twice daily, at the times of the lowest and highest
values. To our knowledge, however, no study has
determined whether or not the timing of the lowest and
highest daily PEF values is altered by inhaled steroids in
asthmatic patients.
Cosinor analysis has been used to evaluate circadian
rhythms of pulmonary function in normal and asthmatic
subjects. Circadian rhythms have previously been detected,
not only in normal subjects but also in patients with
asthma. Asthma may be associated with an exaggerated
normal circadian rhythm (6). We investigated the optimal
time for measuring PEF in patients with mild to moderate
asthma who received inhaled b-agonists as needed, both
before and after treatment with inhaled beclomethasone
dipropionate (BDP).# 2000 HARCOURT PUBLISHERS LTD
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SUBJECTS
Patients with mild to moderate asthma (FEV1460%
predicted) who had received no previous treatment were
entered into this study. Smokers and patients with severe
asthma (FEV160% predicted) were excluded. All enrolled
patients met the American Thoracic Society diagnostic
criteria for asthma (7). PEF was measured throughout the
study.
PEF MEASUREMENT
Patients were instructed in the use of a peak flow meter
(Assess, Healthscan Products Inc., Cedar Grove, New
Jersey, U.S.A.), and were requested to record their PEF
values and the time of measurement throughout the study.
We carefully instructed patients on how to use a peak flow
meter as follows: ‘Do the following five steps with your
peak flow meter: (i) move the indicator to the bottom of the
numbered scale; (ii) stand up; (iii) take a deep breath, filling
your lungs completely; (iv) place the mouthpiece in your
mouth and close your lips around it: do not put your
tongue inside the hole; (v) blow out as hard and fast as you
can in a single blow; write down the number you get, but if
you cough or make a mistake, don’t write down the
number, do it over again.’ The patients recorded the value
and time of the best of three expirations four times daily, on
awakening, around noon, in the evening and at bedtime,
before inhaling a b-agonist as needed for symptoms. If the
patient inhaled a b-agonist on demand, PEF was measured
4 h or more after administration. Daily PEF variability was
calculated according to the following formula: [(highest
PEF 7 lowest PEF)/mean PEF] (%).
STUDY DESIGN
After 2 weeks of observation, BDP 400 mg/d was given to
the patients for 14 days. The eect of BDP 400 mg/d was
evaluated on the basis of daily PEF variability and
symptoms on the 12th, 13th and 14th days of treatment.
If daily PEF variability was no more than 20% orFIG. 1. Protocol. Stable: no symptoms or variability 20% on th
treatment; unstable: symptoms or variability20% on the 12th, 1symptoms disappeared, BDP 400 mg day71 was continued;
if daily PEF variability was more than 20% or symptoms
persisted, the dose of BDP was increased to 800 mg day71.
The eect of BDP 800 mg day71 was evaluated on the basis
of daily PEF variability and symptoms on the 12th, 13th
and 14th days of treatment. If daily PEF variability was no
more than 20% or symptoms disappeared, BDP 800 mg
day71 was continued; if daily PEF variability was more
than 20% or symptoms persisted, the dose of BDP was
increased to 1200 mg day71 (Fig. 1). BDP was inhaled by
means of a spacer device (Inspir Ease, Schering-Plough
K.K., Osaka, Japan) four times daily after measuring PEF.
A b-agonist (procaterol) was taken as needed for symp-
toms, not regularly, during the study.
STATISTICAL ANALYSIS
Results are expressed as means+SE. Values of P005 were
considered to indicate statistical significance. We used
cosinor analysis to assess the circadian rhythm of PEF.
Cosinor analysis uses a least-squares method to test the
goodness of fit of the raw data to a sinusoidal waveform to
evaluate the characteristics of rhythms. Cosinor analysis
involves three variables, mesor (value about which oscilla-
tion occurs), amplitude (half the dierence between the
highest and lowest values) and acrophase (timing of high
point, in degrees) (Fig. 2). This method permits a
quantitative definition of rhythms in individuals, specific
groups, or populations. Single cosinor analysis finds its
most obvious application in analysing a single series of
values from an individual. A comparison of individual
rhythms can be made on the basis of such analyses. Group
mean–cosinor analysis is used for comparison of rhythms
between specific groups, and population mean–cosinor
analysis for comparison between populations, based on
data obtained by cosinor analyses (6,8,9). The hypothesis
that the amplitude is zero can be reflected with P005,
implying a statistically significant rhythm. We used single
cosinor analysis to investigate the circadian rhythm of PEF,
calculated on the basis of PEF and the times of measure-
ment in each patient, both for the last 3 days of the 2 weeks
observation period and for the last 3 days of the treatment
period, i. e. after having achieved good control for at least 2e 12th, 13th and 14th days of the BDP 400 or 800 mg day71
3th and 14th days of the BDP 400 or 800 mg day71 treatment.
FIG. 2. Cosinor analysis. Rhythms are shown as vectors with length proportional to amplitude and angle indicating phase.
Error ellipses enclose the 95% confidence limits for amplitude and phase. Scale: 100 l min71.
TABLE 1. Patient characteristics (n22)
n
Age (year) 320+36
Range 16–69
Sex
Male: Female 18:4
Smoking history
Never smoker 21
Ex-smoker 1
Current smoker 0
Spirometry
VC(l) 372+042
%VC 1013+92
FEV1(l) 258+034
%FEV1(l) 671+52
Skin prick testing
Atopic 11
Non-atopic 11
BDP dose (mg day71) 1000+603
Range 400–1200
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those indicating continuation of the same dose of BDP. The
circadian rhythm of PEF was investigated before and after
treatment with BDP by group mean–cosinor analysis. In
addition, we assessed the circadian rhythm of PEF before
and after treatment with BDP by population mean–cosinor
analysis, and we determined the most appropriate times to
measure PEF twice daily.
Results
Table 1 lists the clinical characteristics of the patients
(n22) and the dose of BDP required for good control in
the present study. Good control was obtained in all
patients. FEV1 obtained during good control was within
the normal range in all patients. The mean dose of BDP
required for good control was 1000+603 mg day71 (range,
400–1200 mg day71). All patients had significant circadian
rhythms detectable by single cosinor analysis, both during
the observation and treatment periods. The mesor increased
significantly in all except one patient, and the amplitude-
acrophase changed significantly in seven patients (Table 2).
Analysis by the group mean–cosinor method showed that
the 95% confidence limit of the mean mesor was 3788+58
l min71, that of the mean amplitude was 539+62 l min71,
and that of the mean acrophase was at 16:26+0:23 before
treatment. After treatment, the 95% confidence limit of the
mean mesor was 5280+38 l min71, that of the mean
amplitude was 376+42 l min71, and that of the mean
acrophase was at 16:35+0:22. The mesor test and the
amplitude-acrophase test revealed significant dierences
between before and after treatment (Fig. 3). Population
mean–cosinor analysis showed that the 95% confidence
limit of the mean mesor was 3788+591 l min71, that of
the mean amplitude was 539+134 l min71, and that of the
mean acrophase was at 16:26+0:32. After treatment, the95% confidence limit of the mean mesor was 5280
+619 l min71, that of the mean amplitude was 376
+122 l min71, and that of the mean acrophase was at
16:35+0:32 (Fig. 4). PEF was lowest at 04:30 h and highest
at 16:30 h in patients with mild to moderate asthma, both
before and after treatment with BDP. Patients with mild to
moderate asthma had a circadian rhythm, both during the
observation and treatment periods. The results of the mesor
and the amplitude-acrophase tests were significant. The
mean mesor increased significantly, and the mean ampli-
tude decreased significantly after treatment. The mean
acrophase did not change.
TABLE 2. Single Cosinor Analysis of data collected during observation and during treatment with BDP (the mesor increased
significantly in all except for one patient and the amplitude-acrophase changed significantly in seven patients)
Observation Treatment
Case Mesor
(lm71)
Amplitude
(lm71)
Acrophase
(h:m)
Mesor
(lm71)
Amplitude
(lm71)
Acrophase
(h:m)
Mesor
test
Amplitude-
acrophase test
1 171+12 29+12 16:48+1:28 629+17 35+17 16:13+1:40 s n.s.
2 239+12 41+13 14:36+1:00 336+6 22+7 16:03+1:00 s s
3 573+24 51+31 18:04+2:03 692+27 42+33 15:40+3:24 s n.s.
4 689+17 60+18 14:52+1:01 797+5 9+5 15:39+2:10 s s
5 224+12 47+12 16:30+0:58 260+10 13+11 14:56+2:54 s s
6 201+20 50+22 16:49+1:32 349+14 33+15 16:27+1:32 s n.s.
7 493+26 73+27 16:22+1:16 600+13 17+14 15:07+3:03 s s
8 579+37 85+37 17:12+1:28 654+22 63+26 17:06+1:22 s n.s.
9 407+29 69+28 16:50+1:25 578+15 46+18 17:30+1:13 s n.s.
10 316+59 75+63 16:12+3:01 566+35 72+38 16:51+1:44 s s
11 538+24 70+26 14:24+1:13 544+17 34+19 14:58+1:52 n.s. n.s.
12 373+35 90+44 16:51+1:25 501+18 63+23 16:35+1:08 s n.s.
13 398+30 41+34 17:15+3:00 556+16 36+18 17:38+1:38 s n.s.
14 327+43 59+49 15:53+3:56 690+29 47+33 17:11+2:41 s n.s.
15 435+67 87+80 17:00+4:24 730+17 67+20 17:46+0:54 s n.s.
16 285+14 27+16 17:03+1:52 387+10 28+12 15:58+1:21 s n.s.
17 350+9 30+10 16:38+1:05 417+5 10+6 15:17+2:09 s s
18 275+15 61+16 16:51+0:54 414+10 26+11 16:47+1:25 s s
19 309+21 49+22 16:03+1:30 466+11 56+13 16:11+0:44 s n.s.
20 411+28 53+29 15:35+1:46 535+22 59+23 15:59+1:18 s n.s.
21 422+13 35+13 17:07+1:21 510+10 34+10 1708+1:06 s n.s.
22 321+23 37+24 17:11+1:58 413+11 27+14 15:54+1:42 s n.s.
Values are +95% confidence limit.
s: significant (P5005); n.s.: non-significant (P4005)
FIG. 3. Group mean–cosinor analysis. The mean
acrophases are not significantly dierent between before
and after treatmentwith BDP. N26, Scale: 100 l min71.
FIG. 4. Population mean–cosinor analysis. The mean
acrophases are not significantly dierent between before
and after treatment with BDP. N26, Scale: 100 l min71.
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PEF measurement has been advocated for the objective
assessment of asthma since the 1970s, when inexpensive and
reliable portable devices became available (10), and is now
widely used in the management of asthma (11–13). Because
the measurement of PEF depends on eort and technique,
patients require instruction, demonstration and frequent
review of technique. We carefully showed patients how to
use a peak flow meter. If one can use the device,
quantification of PEF measurement is valuable in assessing
the degree of airflow obstruction (14), disease severity (15)
and daily variability in lung function. PEF can also be used
to monitor the response to therapy (16), investigate specific
allergens (17) and detect asymptomatic deterioration, which
occurs in patients with severe asthma (18,19). PEF at a
single point in time reflects airway obstruction in patients
with asthma, but daily PEF variability is a marker of
airway lability rather than of airway obstruction (20). Daily
PEF variability is a useful index because the level of airway
hyper-responsiveness usually correlates with the clinical
severity of asthma as well as with medication requirements
(21); moreover, fluctuations in morning and evening PEF
correlate well with histamine-induced airway hyper-
responsiveness (4,22). Recently, some reviews recommend
that b-agonists should be inhaled as needed for symptoms,
rather than regularly (11–13). To assess daily PEF
variability in patients receiving inhaled b-agonists on an
as-needed basis, we have to measure PEF twice daily, when
PEF is lowest and highest.
Corticosteroids are currently the most eective anti-
inflammatory drugs, and inhaled corticosteroids are widely
used for the treatment of persistent asthma. Inhaled
corticosteroids improve lung function (23–26), decrease
airway hyper-responsiveness (23,24,26) and reduce symp-
toms (23,24,26) in patients with asthma. We used cosinor
analysis to assess the circadian rhythms of PEF and to
determine the optimal time for measuring PEF in patients
with mild to moderate asthma, not only before but also
after treatment with inhaled BDP. Cosinor analysis is
commonly used to detect circadian rhythms. It may be
inappropriate for the investigation of low amplitude
circadian rhythm (27), but has the advantage of requiring
only a small number of data for each rhythm cycle,
provided the data are well distributed. The exact time of
readings is also taken into account, so that any readings
taken later than intended can still be used without
impairing the accuracy of rhythm detection (6,8,9).
Circadian rhythms have been demonstrated by cosinor
analysis, both in normal subjects and in asthmatic patients
(6,9). Hetzel and Clark reported that the mean acrophase
was at 15:57 in asthmatic patients, but in their study
patients were treated with corticosteroids or bronchodila-
tors. Although circadian rhythms are predicted to be
aected by bronchodilators, their results were close to our
results in acrophase. In our study, each patient received
only BDP at the minimal required for good control. All
patients had circadian rhythms in PEF on single cosinor
analysis, not only before but also after treatment with BDP.
The circadian rhythms of PEF are predicted to beinfluenced by sleep patterns. However, in our study all
patients worked during the daytime and there were no big
dierences in acrophases among patients on single cosinor
analysis. Group mean–cosinor analysis and population
mean–cosinor analysis detected circadian rhythms, both
before and after treatment. These results imply that the
group and the population with mild to moderate asthma
had circadian rhythms before and after treatment with
BDP. The mean-mesor increased significantly and the
mean-amplitude decreased significantly after treatment,
but the mean-acrophase did not change. The mean-
acrophase was at 16:26+0:32 before treatment and at
16:35+0:22 after treatment. These results suggest that
patients with mild to moderate asthma have circadian
rhythms in PEF both before and after treatment with only
BDP. It is very interesting that the acrophase does not
change during treatment with BDP alone. In addition, in
general, PEF is lowest at 04:30 h and highest at 16:30 h in
patients with mild to moderate asthma. We conclude that if
one needs to assess PEF twice a day, this should ideally be
done at 04:30 h and 16:30 h, not only before but also after
treatment with BDP. Practically speaking, it is recom-
mended to measure PEF at a time close to 04:30 h, either on
awakening or at bedtime, and at 16:30 h.
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